Traders should monitor upcoming IND submission (Q3 2026) and trial initiation (Q4 2026) as near-term catalysts. The $10.5M financing de-risks near-term execution, but further dilution is likely ahead of clinical data readout in 2027. Positive early data could drive significant upside given the company's small $6M market cap.
Price Chart
Executive Summary
Ernexa Therapeutics announced preclinical success for its lead candidate ERNA-101 in ovarian cancer, with plans to submit an IND in Q3 2026 and initiate a first-in-human trial in Q4 2026. The company highlighted upcoming milestones over the next 18 months, supported by a recent $10.5M financing, as it transitions to a clinical-stage biotech.
Key Facts
- Preclinical data show deep and durable tumor regressions with ERNA-101 in combination with PD-1 blockade in ovarian cancer models
- IND submission for ERNA-101 expected in Q3 2026; first-in-human Phase 1 trial to start in Q4 2026 for platinum-resistant ovarian cancer
- Company completed Pre-IND meeting with FDA and reduced G&A expenses by 61% YoY in 2025
- Recent $10.5 million financing supports advancement through key milestones
- Initial clinical data readout expected in 1H 2027, with potential Phase 2 advancement via co-development partner in 2H 2027
Financial Impact
$10.5 million in recent financing; no direct revenue or EPS impact yet as company remains pre-revenue
Risk Factors
- High risk associated with early-stage biotech: clinical trials may fail despite strong preclinical results
- Dilution risk as additional capital will likely be needed before 2027 data readout
- No guaranteed partnership or co-development deal in Phase 2
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265550 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.08 | awaiting T+5 | — | $1.94 (−6.51%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $1.94 (−7.18%) |
Oct 1, 2026 25d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $1.94 (−34.46%) |
Sep 30, 2026 26d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $1.94 (−39.37%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Jul 14, 2026 14w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $1.94 (−67.99%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $1.94 (−72.40%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $1.94 (−67.06%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $1.94 (−82.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers